GSK 2330672
GSK 2330672 Basic information
- Product Name:
- GSK 2330672
- Synonyms:
-
- GSK 2330672; GSK-2330672
- GSK 2330672
- 3-[[(3R,5R)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1λ6,4-benzothiazepin-8-yl]methylamino]pentanedioic acid
- Pentanedioic acid, 3-((((3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl)methyl)amino)-
- CS-2639
- Iinerixibat
- linerixibat
- Iinerixibat (GSK2330672)
- CAS:
- 1345982-69-5
- MF:
- C28H38N2O7S
- MW:
- 546.68
- EINECS:
- 604-604-1
- Mol File:
- 1345982-69-5.mol
GSK 2330672 Chemical Properties
- Boiling point:
- 730.8±60.0 °C(Predicted)
- Density
- 1.218±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMF: 5 mg/ml; DMSO: 2 mg/ml; PBS (pH 7.2): 0.2 mg/ml
- form
- A crystalline solid
- pka
- 3.27±0.10(Predicted)
- color
- White to off-white
- InChIKey
- CZGVOBIGEBDYTP-VSGBNLITSA-N
- SMILES
- C(O)(=O)CC(NCC1C=C2S(=O)(=O)C[C@](CCCC)(CC)N[C@H](C3=CC=CC=C3)C2=CC=1OC)CC(O)=O
GSK 2330672 Usage And Synthesis
Description
GSK2330672 is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT; IC50s = 42, 2.1, and 1.9 nM for human, mouse, and rat ASBT, respectively). In vivo, GSK2330672 (0.05 mg/kg) stimulates fecal bile acid secretion, reduces hemoglobin A1c (HbA1c) and plasma glucose levels, and increases total GLP-1 and plasma insulin in Zucker diabetic fatty (ZDF) rats.
Uses
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment[1][2][3].
in vivo
Linerixibat (GSK2330672; 0.05-10 mg/kg; oral gavage; twice daily; for 14 days; male ZDF rat) treatment lowers glucose in an animal model of type 2 diabetes[1].
| Animal Model: | Male Zucker Diabetic Fatty (ZDF) rat[1] |
| Dosage: | 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg |
| Administration: | Oral gavage; twice daily; for 14 days |
| Result: | Led to a 1.30-1.64% reduction in hemoglobin A1c (HbA1c), a greater than 50% reduction in nonfasted plasma glucose to below 200 mg/dL, and statistically significant higher plasma insulin. |
References
[1] Wu Y, et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. DOI:10.1021/jm400459m
[2] Wang Y, et al. HNF4α Regulates CSAD to Couple Hepatic Taurine Production to Bile Acid Synthesis in Mice. Gene Expr. 2018 Aug 22;18(3):187-196. DOI:10.3727/105221618X15277685544442
[3] Linerixibat (GSK2330672) granted Orphan Status. September 24, 2019.
GSK 2330672Supplier
- Tel
- 0550-5196001 15000891977
- wj520wjxby@126.com
- Tel
- 17702719238 18971495150;
- sales@sun-shinechem.com
- Tel
- 025-83697070
- info@chemlin.com.cn
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- +1 (866) 930-6790
- info@adooq.com
GSK 2330672(1345982-69-5)Related Product Information
- GSK2814338
- GSK-2256098
- GSK-25
- S)-1-(sec-butyl)-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-3-Methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxaMide
- 7Methyl-5-(1-{[3-(trifluoroMethyl)phenyl]acetyl}-2,3-dihydro1Hindol-5-yl)7Hpyrrolo[2,3d]pyriMidin-4-aMine
- GSK 2801
- GSK2636771
- GSK2879552
- GSK2795039
- GSK2838232